Spruce Biosciences, Inc. (SPRB)
NASDAQ: SPRB · Real-Time Price · USD
9.52
-0.06 (-0.63%)
At close: Sep 17, 2025, 4:00 PM EDT
9.24
-0.28 (-2.94%)
After-hours: Sep 17, 2025, 5:54 PM EDT
Spruce Biosciences Revenue
Spruce Biosciences had revenue of $1.30M in the twelve months ending June 30, 2025, down -86.43% year-over-year. In the year 2024, Spruce Biosciences had annual revenue of $4.91M, down -51.32%.
Revenue (ttm)
$1.30M
Revenue Growth
-86.43%
P/S Ratio
4.18
Revenue / Employee
$61,857
Employees
21
Market Cap
5.36M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.91M | -5.18M | -51.32% |
| Dec 31, 2023 | 10.09M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
SPRB News
- 2 days ago - Spruce Biosciences Resumes Trading on the Nasdaq Capital Market - Business Wire